- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
This is the main Moderna stock price chart and current quotes. You can find more details about MRNA stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
57.71
+3.85(+7.15%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
54.62
57.93
52 wk Range
22.28
85.60
MRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
54.6257.93
52 wk Range
22.2885.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRNA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
50.84
Downside
-11.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
4 Buy
16 Hold
3 Sell
Ratings:
23 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 50.84
(-11.90% Downside)
Moderna Inc SWOT Analysis
Market Dominance | The company maintains commanding 42% U.S. COVID-19 vaccine market share while leveraging proven mRNA platform technology across multiple therapeutic areas |
Profitability Path | Cost reduction initiatives and manufacturing expansion aim to offset projected losses of $7.95 per share in FY2026, with 10% revenue growth expected |
Analyst Targets | Average price target stands at $27, reflecting measured optimism about the company's transition from COVID-19 dependence to diversified revenue streams |
Pipeline Progress | Moderna advances oncology programs with melanoma treatment showing 67% response rates, while flu/COVID combination vaccines near approval for 2027 launch |
Moderna Inc Earnings Call Summary for Q2/2026
- Moderna posted Q2 2026 adjusted loss of $1.97/share, beating estimates of $2.03, on revenue of $145M, up 2% YoY; shares rose 3.67% premarket.
- Company narrowed net loss to $782M from $825M YoY through cost controls; R&D down 7%, SG&A down 6%, and cash costs reduced 10% versus Q2 2025.
- Moderna lowered 2026 operating expense guidance by $200M to $4.7B and cut cash cost outlook by $200M to $4.0B while maintaining growth investments.
- Management reaffirmed up to 10% revenue growth for 2026, expects stronger H2 with Q3 representing ~55% of second-half revenue; year-end cash projected at $4.7B-$5.2B.
- Key catalysts include Aug. 5 FDA decision on flu vaccine mRNA-1010 and H2 2026 interim melanoma data; appointed Ester Banque as chief commercial officer.
Last Updated: 07/31/2026, 09:17 AM
Read Full TranscriptModerna investor slides for Q2/2026
Last Update: Jul 31, 2026
See full investor slides
Earnings
Latest Release
Jul 31, 2026
EPS / Forecast
-1.97 / -2.03
Revenue / Forecast
100M / 99.91M
Compare MRNA to Peers and Sector
Metrics to compare | MRNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.3x | −9.3x | −0.4x | |
PEG Ratio | 1.12 | 0.03 | 0.00 | |
Price / Book | 3.4x | 3.7x | 2.6x | |
Price / LTM Sales | 10.3x | 7.6x | 3.0x | |
Upside (Analyst Target) | −21.5% | 58.9% | 50.7% | |
Fair Value Upside | Unlock | 5.8% | 7.2% | Unlock |
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Moderna (MRNA) Stock Price Today?
The Moderna stock price today is 57.71 USD.
What Stock Exchange Does Moderna Trade On?
Moderna is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Moderna?
The stock symbol for Moderna is "MRNA."
What Is the Moderna Market Cap?
As of today, Moderna market cap is 22.85B USD.
What Is Moderna's Earnings Per Share (TTM)?
The Moderna EPS (TTM) is -8.01.
When Is the Next Moderna Earnings Date?
Moderna will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is MRNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Moderna Stock Split?
Moderna has split 0 times.
How Many Employees Does Moderna Have?
Moderna has 4700 employees.
What is the current trading status of Moderna (MRNA)?
As of Aug 07, 2026, Moderna (MRNA) is trading at a price of 57.71 USD, with a previous close of 53.86 USD. The stock has fluctuated within a day range of 54.62 USD to 57.93 USD, while its 52-week range spans from 22.28 USD to 85.60 USD.
What Is Moderna (MRNA) Price Target According to Analysts?
The average 12-month price target for Moderna is 50.84 USD, with a high estimate of 79 USD and a low estimate of 25 USD. 4 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -11.90% Downside potential.
What Is the MRNA Premarket Price?
MRNA's last pre-market stock price is 54.78 USD. The pre-market share volume is 88,760.00, and the stock has decreased by 0.92, or 1.71%.
What Is the MRNA After Hours Price?
MRNA's last after hours stock price is 54.49 USD, the stock has decreased by 0.63, or 1.17%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.